Karolinska Development Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Karolinska Development de winst en omzet met respectievelijk 5.8% en 1.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 6.2% per jaar.

Belangrijke informatie

5.8%

Groei van de winst

6.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	19.6%
Inkomstengroei	1.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0P3C - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2	-24	-25	-25	1
12/31/2025	2	-23	-22	-22	1
12/31/2024	2	-24	-23	-23	1
9/30/2024	2	-29	-26	-26	N/A
6/30/2024	2	-6	-24	-24	N/A
3/31/2024	2	34	-22	-22	N/A
12/31/2023	2	5	-25	-25	N/A
9/30/2023	2	17	-26	-26	N/A
6/30/2023	2	-41	-27	-27	N/A
3/31/2023	2	-87	-27	-27	N/A
12/31/2022	2	-88	-33	-33	N/A
9/30/2022	2	-118	-31	-31	N/A
6/30/2022	2	-72	10	10	N/A
3/31/2022	2	166	10	10	N/A
12/31/2021	2	171	17	17	N/A
9/30/2021	2	276	47	47	N/A
6/30/2021	2	108	2	2	N/A
3/31/2021	2	-106	-6	-6	N/A
12/31/2020	3	-207	-33	-33	N/A
9/30/2020	3	35	-19	-19	N/A
6/30/2020	3	190	-41	-41	N/A
3/31/2020	4	195	-36	-36	N/A
12/31/2019	3	303	-7	-7	N/A
9/30/2019	4	-11	-6	-6	N/A
6/30/2019	4	8	18	18	N/A
3/31/2019	3	32	19	19	N/A
12/31/2018	3	31	13	13	N/A
9/30/2018	3	48	-60	-60	N/A
6/30/2018	3	238	N/A	-56	N/A
3/31/2018	3	185	N/A	-49	N/A
12/31/2017	2	180	N/A	-31	N/A
9/30/2017	5	125	N/A	-6	N/A
6/30/2017	5	-87	N/A	3	N/A
3/31/2017	5	-142	N/A	6	N/A
12/31/2016	5	-217	N/A	-9	N/A
9/30/2016	2	-315	N/A	-32	N/A
6/30/2016	2	-325	N/A	-95	N/A
3/31/2016	3	-904	N/A	-122	N/A
12/31/2015	3	-1,055	N/A	-325	N/A
9/30/2015	4	-980	N/A	-375	N/A
6/30/2015	5	-1,072	N/A	-342	N/A
3/31/2015	5	-608	N/A	-306	N/A
12/31/2014	5	-371	N/A	-108	N/A
9/30/2014	4	-424	N/A	-57	N/A
6/30/2014	5	-396	N/A	-124	N/A
3/31/2014	5	-169	N/A	-54	N/A
12/31/2013	5	-157	N/A	-71	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 0P3C de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 0P3C de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 0P3C de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 0P3C ( 1.8% per jaar) zal naar verwachting langzamer groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van 0P3C ( 1.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 0P3C naar verwachting over 3 jaar hoog zal zijn

Karolinska Development Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

First quarter 2023 earnings released

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Second quarter 2022 earnings released

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Investor sentiment deteriorated over the past week

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Less than half of directors are independent

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven